Bejelentkezés Regisztrálj ingyen

Alimera Sciences Adósság / tőke

Mi az Alimera Sciences Adósság / tőke?

A Adósság / tőke az Alimera Sciences Inc. - 2.33

Mi a Adósság / tőke meghatározása?



Az adósság és a saját tőke aránya a társasági eszközök finanszírozásához használt saját tőke és adósság viszonylagos arányát jelző pénzügyi arány.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Adósság / tőke a Health Care szektor a NASDAQ-on cégekben a Alimera Sciences -hoz képest

Mit csinál Alimera Sciences?

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.

adósság / tőke -hoz hasonló cégek Alimera Sciences